![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.prnewswire.com/news-releases/foamix-announces-publication-of-phase-3-studies-evaluating-fmx103-for-the-treatment-of-papulopustular-rosacea-in-journal-of-the-american-academy-of-dermatology-301000340.html
https://www.prnewswire.com/news-releases/foamix-announces-amzeeq-minocycline-achievement-of-preferred-status-on-express-scripts-national-preferred-formulary-one-of-the-largest-commercial-formularies-in-the-us-300986316.html
https://www.biospace.com/article/releases/foamix-announces-enrollment-completion-of-phase-2-acne-clinical-trial-for-fcd105-minocycline-3-percent-and-adapalene-0-3-percent-combination-foam/?s=95
https://www.biospace.com/article/foamix-and-menlo-therapeutics-merge-to-focus-on-dermatology/?s=79